For two decades, concurrent cisplatin-based chemoradiation was the uncontested standard for locally advanced cervix cancer. That foundation still stands—but 2023–2024 ushered in real upgrades. Today, we’ll cover what to add (and when) for definitive therapy, and how first-line systemic therapy has changed for metastatic and recurrent disease.